Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003386 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00003386: Clinical Trial Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT00003386 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003386, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
Interventions
- DRUG cisplatin
- DRUG carboplatin
- DRUG cyclophosphamide
- BIOLOGICAL autologous tumor cell vaccine
- BIOLOGICAL BCG vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Phase | Phase 2 |
Why NCT00003386 stopped before completion
NCT00003386 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003386 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003386 about?
NCT00003386 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer". RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
What is the current status of trial NCT00003386?
This trial is currently terminated. It is a Phase 2 study. The study started on 1999-07.
What interventions are being tested in trial NCT00003386?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), cyclophosphamide (DRUG), autologous tumor cell vaccine (BIOLOGICAL), BCG vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003386?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia